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Aims: Growth hormone (GH) secretion is pulsatile and secretion varies highly
between individuals. To understand and ultimately predict GH secretion, it is
important to first delineate and quantify the interaction and variability in the biologi-
cal processes underlying stimulated GH secretion. This study reports on the develop-
ment of a population nonlinear mixed effects model for GH stimulation,
incorporating individual GH kinetics and the stimulation of GH by GH-releasing
hormone (GHRH).
Methods: Literature data on the systemic circulation, the median eminence, and the
anterior pituitary were included as system parameters in the model. Population
parameters were estimated on data from 8 healthy normal weight and 16 obese
women who received a 33 μg recombinant human GH dose. The next day, a bolus
injection of 100 μg GHRH was given to stimulate GH secretion.
Results: The GH kinetics were best described with the addition of 2 distribution com-
partments with a bodyweight dependent clearance (increasing linearly from 24.7 L/h
for a 60-kg subject to 32.1 L/h for a 100-kg subject). The model described the data
adequately with high parameter precision and significant interindividual variability on
the GH clearance and distribution volume. Additionally, high variability in the amount
of secreted GH, driven by GHRH receptor activation, was identified (coefficient of
variation = 90%).
Conclusion: The stimulation of GH by GHRH was quantified and significant inter-
individual variability was identified on multiple parameters. This model sets the stage
for further development of by inclusion of additional physiological components to
quantify GH secretion in humans.
K E YWORD S
GH, Growth hormone, growth hormone-releasing hormone, kinetics, NLME model,
stimulation test
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1 | INTRODUCTION
Growth hormone (GH) plays an important role in many biological
processes such as growth and cell reproduction, but also in several
diseases such as pituitary adenomas. GH is secreted by somatotrophs
in the anterior pituitary and can induce a variety of actions, among
which the secretion of insulin-like growth factor-1 (IGF-1), responsible
for a large part of the growth promoting effects of GH.1-3 The
regulation of GH is a complex interaction of stimulatory, e.g. GH-
releasing hormone (GHRH) and ghrelin, and inhibitory hormones,
e.g. somatostatin.1,4 At the arcuate nucleus in the hypothalamus,
neurons secrete pulses of GHRH into the median eminence.5,6 Via the
hypophyseal portal system, GHRH binds to its receptor at the cell
surface of somatotrophs in the anterior pituitary, triggering the
intracellular signalling cascade, which releases GH into the systemic
circulation.7 In response to the increase in GH concentrations in the
blood, somatostatin is released from the periventricular region of the
hypothalamus to inhibit further GH secretion.8 The interaction
between these signals, all having short half-lives, on a somatotroph
results in a highly pulsatile and variable GH profile in plasma.
This variability is further increased in patients with acromegaly,
who commonly have a pituitary adenoma that causes GH hyper-
secretion. The GH concentration–time profiles of these individuals
are more stochastic, with higher basal concentrations and higher
bursts of GH secretion.9 When assessing treatment effectiveness,
sparsely sampled GH or IGF-1 data are commonly used to inform
decision making despite its known risk of misinterpretation due to the
large variability in this patient population.10 The use of modelling and
simulation techniques can improve interpretation of these results and
provide additional information on treatment decisions by incorporat-
ing (patho-)physiological information to describe complex biological
systems, especially in endocrinology.11-13 The simulation of 24-hour
endogenous pulsatile GH profiles could eventually provide important
insight to correctly assess a patient's GH secretion, study the
effectiveness of treatment, or to inform on the optimal design of new
clinical. However, to be able to simulate realistic and patient specific
GH profiles, the feed-forward stimulation of GH by GHRH and the
level of variability in the healthy biological system needs to be quanti-
fied first.
Several attempts have been made to capture the hypothalamic
and pituitary regulation of GH in physiologically based (systems)
models, both in animals and humans.14-20 Unfortunately, these mech-
anistic models did not include information on the variability between
individuals or the variance in the model parameters, thereby assuming
a single typical pulsatile concentration-time profile of endogenous GH
secretion for all individuals. This use of a typical GH profile compli-
cates the ability to judge whether a model is suitable to describe
actual clinical data and can therefore not be used for (clinical trial) sim-
ulations. Existing empirical models of recombinant human GH (rhGH)
do provide information on the interindividual variability in the kinetic
parameters, such as clearance and the volume of distribution, but they
are of limited use when the model needs to be expanded with
physiological information on additional pathways in a different set of
individuals, for which only the point estimate of the model can be
used and the origin of variability in the response cannot be retrieved.
As a first step towards the mechanistic description of endogenous
GH secretion, this study focuses on the quantification of the individ-
ual GH kinetics—after administration of rhGH—and the feed-forward
stimulatory properties of GHRH in healthy and obese women using a
middle-out estimation approach. Therefore, data from experiments
performed in a cross-over design, informing on different parts of the
biological system in the same individual, were integrated in a popula-
tion nonlinear mixed effects (NLME) model with the structural model
based on physiological information.
2 | METHODS
2.1 | Subjects and data
The data for this analysis were obtained from a clinical study that has
been reported previously.21,22 The study was approved by the
Medical Ethics Committee (METC) of Leiden University Medical
Center, Leiden, the Netherlands. All subjects signed an informed
consent form prior to the start of the study and the study was exe-
cuted conforming to Declaration of Helsinki standards.
In this clinical study, 2 experiments were performed in healthy
normal weight (n = 8) and lower (n = 8) or upper (n = 8) body obese
What is already known about this subject
• Growth hormone (GH) secretion is pulsatile and the num-
ber of bursts, the amplitude and the burst interval varies
greatly between individuals.
• Limited information is available on stimulated GH secre-
tion by GH-releasing hormone while accounting for the
individual GH kinetics in humans.
• Existing mechanistic models describing the GH system do
not include variance on the parameters or quantify the
level of interindividual variability, limiting predictive per-
formance for new study designs.
What this study adds
• A population nonlinear mixed effects model of stimulated
GH secretion, developed on literature information and
experimental data, incorporating the individual GH kinet-
ics and the stimulatory effects of GH-releasing hormone
was developed.
• The level of variability on GH clearance, distribution vol-
ume and the GH-releasing hormone secretion parameters
were quantified, with a significant covariate relationship
of bodyweight on GH clearance.
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women (median age = 37 years; interquartile range = [33–42 years],
weight = 81.7 kg [69.8–95 kg], body mass index = 30.3 kg/m2
[25.1–43.2 kg/m2]). All subjects participated in 2 experiments: (1) the
administration of rhGH; and (2) a GH stimulation test with GHRH. At
the start of the rhGH experiment, a 2.5-hour somatostatin infusion
(50 μg/m2/h) was started to inhibit endogenous GH release and
plasma samples were obtained every 10 minutes for GH analysis. One
hour after the start of the somatostatin infusion, 33 μg of 22-kDa
rhGH was administered as a 5-minute intravenous infusion, after
which the plasma sampling was intensified to every 5 minutes for the
first hour after dosing. Then, plasma sampling was reduced to every
10 minutes until the end of the experiment (t = 1.5 h after dosing).
The day after experiment 1, a GH stimulation test was performed.
Three plasma samples were taken at 10-minute intervals after which
the subjects received a fixed intravenous bolus dose of 100 μg GHRH.
Samples were taken at 10-minute intervals up to 3.5 h after dosing.
For modelling purposes, the GHRH dose was converted to nmol by
the molecular weight.
The obese women in the study additionally followed a weight
loss diet and returned when they had lost 50% of their excess
weight, after which the rhGH and stimulated GH occasions were
repeated.21 Due to the time between visits and the loss of excess
weight, the data of both visits were treated as originating from dif-
ferent individuals.
Serum 22-kDa GH was measured by immunofluorometric assay
(Delphia hGH kit, coefficients of variation ranging from 1.6 to 8.4%)
with a lower limit of quantification (LLOQ) of 0.01 ng/mL. Data below
the LLOQ were fixed to the LLOQ for analysis.
Additionally, in-house data on the rhGH experiment in 15 healthy,
normal weight female volunteers, subjected to an identical experimen-
tal procedure, were added to the dataset.
2.2 | Model development
To distinguish between the different sources of variability within this
population, model development was performed using the middle-out
approach,23 in which literature information on the system (system
parameters) was combined with the estimation of population
parameters, driven by the available data. This method was applied by
first quantifying the individual GH kinetics after administration of
rhGH, followed by adding the stimulatory properties of GHRH on GH
secretion.
The model structure was based on physiological information of
the pituitary and the somatotropic axis. The main physiological com-
ponents that were included were the systemic circulation, the median
eminence and the infundibular stalk, the anterior pituitary and the
GHRH receptor at the extracellular surface of the somatotrophs.
Unidirectional blood flow from the median eminence to the anterior
pituitary and the systemic circulation was assumed, and system
parameters were extracted from literature.
Population parameters were estimated using a population NLME
modelling approach. A sensitivity analysis was performed on
parameters that suffered from numerical instability. Inter-individual
variability on population parameters, assuming a ln-normal distribu-
tion, was tested for a significant (P < .01) improvement in model fit.
The investigated residual error structures were additive, proportional
or a combination of additive and proportional.
Multiple variables (covariates) were explored to resolve the
unexplained variability in the population: age, height, bodyweight,
body mass index and body surface area. Covariate relationships were
explored by visualization of the posthoc Bayesian estimates vs the
covariates, and judged based on their Pearson correlation coefficient.
Potential relationships were tested in the model using linear or power
relationships and judged on a significant improvement in model fit
(P < .01) with a backward elimination step (P < .01).
2.2.1 | GH kinetics
Structural model development explored the addition of 1 or 2 single
adjusting compartments (SACs), originating from the systemic
circulation in order to encompass the distribution tissues that are in
fast or slow equilibrium with the plasma compartment.24 The
improvement in model fit after the inclusion of a baseline secretion
parameter (GH baseline) of endogenous GH, mimicking endogenous
GH release not fully blocked by the administered somatostatin, was
investigated.
2.2.2 | GH stimulation
After development of the GH kinetics section of the model, the esti-
mated population parameters for the GH kinetics were fixed, thereby
linking the kinetics of GH to the individual response of stimulation by
GHRH. The GHRH receptor activation rate (kact), the receptor inacti-
vation rate (kinact), and the amount of GH released by a bound GHRH
receptor (GHRH-stimulated secretion) were estimated. The inclusion of
a transit compartment, causing a delay between the activation of the
GHRH receptor and the release of GH in the anterior pituitary, was
explored. A baseline secretion parameter, independent of the exoge-
nous GHRH, as was tested in the GH kinetics model, was tested for
significance. Additionally, it was explored whether there was a signifi-
cant improvement in the model fit after the inclusion of the individual
posthoc Bayesian estimates for the GH kinetics compared to the
population parameter estimates.
2.2.3 | Local sensitivity of system parameters
System parameters that were included as point estimates in the
models were subjected to a local sensitivity analysis. These parame-
ters were increased or decreased by a factor of 2 or 10, and the
impact on the area under the curve (AUC) for GH in plasma was
evaluated up to 4 hours after GHRH administration by simulation of
500 concentration–time profiles while including interindividual
VAN ESDONK ET AL. 1577
variability and residual error. To assess whether the estimated
population parameters could account for a possible bias in the system
parameters, the increase and decrease of the system parameters were
combined with a re-estimation step of the population parameters. The
resulting parameter estimates were then included in a new simulation
(n = 500) and judged on a bias with the original model.
2.3 | Model evaluation and internal validation
Models were evaluated on basis of the objective function value
(OFV; −2 log-likelihood), numerical evaluation, and goodness-of-fit
(GOF) graphs.25 A significant (P < .01) improvement in the model fit
was based on a drop in the OFV of minimally 6.64 points after addi-
tion of 1 additional degree of freedom in a nested model. The rela-
tive standard errors (RSEs) of population parameters and η-shrinkage
were considered acceptable when below 50% and 30%, respectively.
The condition number, the ratio of the highest to lowest eigenvalue,
was used to identify model overparameterization and should remain
under the value of 1000. GOF graphs included the population
(PRED) and individual model predictions (IPRED) vs observations,
which should show a homogenous scatter around the line of unity.
The conditional weighted residuals with interaction (CWRESI) vs
PRED and time after dose should have the majority of the data
between the [−2,2] interval and be homogenously distributed around
0. The GOF plots were checked for outliers and structural model
misspecifications.
Models were internally validated using a nonparametric bootstrap
with 1000 samples in order to compare the mean bootstrap results
and the 95% confidence interval with the model parameter estimates,
after resampling from the original dataset. Models were further
internally validated using a confidence interval visual predictive check
(VPC), which was created separately for the GH part of the model
(data from experiment 1) and the feed-forward stimulation model
(data from experiment 2). The median and 80% prediction interval of
the simulated model, with their corresponding 95% confidence inter-
vals, were obtained from 500 simulations of the original dataset. The
80% distribution of the data was compared to the simulated intervals
and judged on structural bias and the ability to correctly capture the
variability in the data.
2.4 | Software
Data transformation and graphical analysis was performed in R
(V3.5.1).26 NLME modelling was performed in NONMEM V7.327 in
conjunction with Perl-speaks-NONMEM V4.6.0.28
2.5 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked
to corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY.
3 | RESULTS
3.1 | Model development
3.1.1 | System parameters
The system parameters that were obtained from literature on the
volume of the systemic circulation, the pituitary blood flow and the
kinetics of GHRH are depicted in Table 1. The total volume of the
median eminence and the infundibular stalk compartment was
approximated using a truncated cone formula, based on magnetic
resonance imaging results.33 For GHRH, the distribution volume was
assumed to be equal to the volume of the extracellular fluid with fast
distribution kinetics due to the short half-life of GHRH, mimicking
1-compartment distribution kinetics.36
The blood flow kinetics of hypophyseal arteries in humans was
essential in the development of this model, but was to our knowl-
edge not reported in the literature. However, this blood flow to the
pituitary could be correlated with the blood flow in the ophthalmic
artery (OA), since the OA branches of the internal carotid artery at
the same location as the superior hypophyseal artery (SHA; C6).
The OA blood flow has been quantified as 4% of the total cerebral
flow (28.68 mL/min) with an artery diameter of ~1.25 mm.32,37 The
SHA, with a diameter of ~0.5 mm, further splits into the inferior
TABLE 1 Overview of physiological parameters identified in
literature
Parameter Value Reference
Plasma volume (mL) (40.5*HT) +
(8.4*WT) - 4811
29
Red cell volume (mL) (16.4*HT) +
(5.7*WT) - 1649
29























HT, height in CM; WT, bodyweight in kg.
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hypophyseal artery, of which the remainder passes through the
median eminence and the infundibular stalk to the anterior pitui-
tary.38 As such, it was assumed that the blood flow to the anterior
pituitary was solely based on the difference in diameter between
the OA and the SHA, resulting in an approximation of the blood
flow of 11.47 mL/min. As plasma concentrations were quantified,
the blood flow was corrected for by the ratio between plasma and
red cell volume, based on the weight and height of a subject
(Table 1).29
The GHRH receptor activation and inactivation rates (kact and
kinact) were estimated as population parameters in the model using
the data from the GH stimulation test. Since the GHRH receptor
density on somatotrophs was unknown, no mass transfer between
the anterior pituitary compartment and the GHRH receptor could be
included. Therefore, the total amount of available GHRH receptors
was fixed to 1.
The schematic structure of the model for GH and GHRH is
depicted in Figure 1. The ordinary differential equations of the model,
with the parameterization of all rate constants and compartment
initializations, and the NONMEM model control stream is available in
Supporting Information 1.
3.1.2 | GH kinetics
A total of 11 observations were below the LLOQ, all before the
administration of rhGH. Exploratory analysis of the data at the start of
the somatostatin infusion (t = −1 h) showed an initial wide scatter
followed by a clear reduction in plasma GH concentrations until rhGH
administration at t = 0 h (Figure 2).
The initial model structure overestimated the observations and
the addition of SACs was explored. The addition of 2 peripheral SACs
F IGURE 1 Model structure with the
growth hormone-releasing hormone
(GHRH) and growth hormone
(GH) kinetics. ECF, extracellular fluid;
SAC, single adjusting compartment; QSAC,
blood flow between plasma and SAC;
Qpituitary, pituitary (blood) flow; kel-GHRH,
elimination rate constant for GHRH;
CLGH, clearance of GH; kact, rate constant
for receptor activation; kinact, rate
constant for receptor inactivation
F IGURE 2 Visual predictive check of plasma
growth hormone concentrations relative to the
time of recombinant human growth hormone
(rhGH) administration (vertical dashed line). The
black dots represent the observations, with their
10–50–90% distribution (black dashed lines). The
shaded areas represent the 95% confidence
intervals of the median prediction (red) and the
10th and the 90th prediction interval (blue)
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in the model provided a significant improvement in the model fit
compared to the additional of a single SAC. However, the inter-
compartmental flow (QSAC-fast) was high and could not be accurately
estimated, indicating a fast equilibrium between the systemic circula-
tion and this distribution compartment. This value was therefore fixed
to 10 000 L/h to allow a quick/instantaneous equilibrium, which was
required to accurately describe the data. A sensitivity analysis on the
QSAC-fast (range: 1000–5*10
5 L/h) did not result in significant changes
in the population parameter estimates or the OFV. The inclusion of a
0-order baseline GH secretion (GH baseline) in the pituitary compart-
ment, resembling limited endogenous GH secretion despite somato-
statin blockage, improved the model fit in the low concentration
ranges and significantly reduced the OFV. Significant interindividual
variability was included on: GH clearance (CLGH), GH baseline and the
distribution volume of the SAC compartment in slow equilibrium
(VSAC-Slow).
Visual exploration of the covariate correlations suggested a rela-
tionship between an individual's CLGH and bodyweight. The inclusion
of a linear covariate relationship (Figure 3) gave the highest reduction
in OFV (−18 points) and reduced the η-distribution correlation plot to
a homogenous scatter around 0, superior to the inclusion of a power
relationship. The coefficient of variation of CLGH was reduced from
19.8 to 16.5%, indicating that bodyweight accounted for a small but
significant explanation of the variability on CLGH. No other covariate
relationships were identified.
The GOF plots showed an adequate model fit, indicated by the
close scatter around the line of unity in the PRED and IPRED vs
observations (Figure S1A, B). The wider distribution in the lower
concentration region of the PRED originated from the pre-rhGH
dose observations. The homogenous scatter around 0 for the
CWRESI indicates no structural model misspecifications over the
concentration range or vs time after dose (Figure S1C, D). The condi-
tion number was low (6.89) and the RSEs of population parameters
were all below 30%. The final parameter estimates for the GH kinet-
ics are given in Table 2. The VPC (Figure 2) shows that the model
was able to capture the general trend and the variability in the popu-
lation. However, 1 subject showed consistently high values outside
of the 80% prediction interval. The exclusion of this individual did
not change the parameter estimates, except for a nonsignificant
decrease in the slope of the covariate relationship from 0.185 to
0.157 L/h/kg.
3.1.3 | GH stimulation
Simultaneous estimation of kact, kinact, and the GHRH-stimulated
secretion parameters resulted in numerical instability of the model.
Due to the short half-life of GHRH and the quick onset of the GH-
releasing effects of GHRH, the kact needed to be fixed in order to
improve the numeric stability. Based on a sensitivity analysis on kact,
a value of 100/nmol GHRH*h was implemented in the model, which
resulted in the lowest OFV. The addition of a transit compartment
F IGURE 3 Posthoc Bayesian estimates of growth hormone
(GH) clearance vs the bodyweight of subjects. Dashed line indicates
the included linear covariate relationship on GH clearance. Red,
healthy normal weight; green, lower body obese; blue, upper body
obese














26.5 [3.65] - 26.58
[23.90–30.09]
VSAC-Fast (L) 1.17 [29.4] - 1.26 [0.27–2.3]
QSAC-Fast (L/h) 10 000
a - -
VSAC-Slow (L) 2.29 [6.63] - 2.27 [1.95–2.58]




1.04 [9.49] - 1.03 [0.75–1.36]
ω2 CLGH 0.0268 (16.5) 2.41 0.0250
[0.013–0.041]










CLGH equation, CLGH-intercept + CLGH-slope* (bodyweight – 70); RSE, relative
standard error; CV%, coefficient of variation; CI, confidence interval; GH,
growth hormone; SAC, single adjusting compartment.
aIndicate fixed parameter.
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between the activated receptor and the GHRH-stimulated secretion
lowered the OFV by 17 points but increased the RSE's from 2% to
62% for kinact and from 20 to 57% for the GHRH-stimulated secretion,
and was therefore excluded from the structural model. The inclusion
of the posthoc Bayesian estimates of the individual GH kinetics
significantly improved the model fit (ΔOFV = −84). Significant inter-
individual variability was identified on the GHRH-stimulated secretion,
which lowered the OFV by 1557 points (coefficient of varia-
tion = 89.7%). No covariates were identified that were explanatory
of this variability.
The model parameter estimates of the GH stimulation part of the
model are reported in Table 3. The confidence interval VPC is shown
in Figure 4, which shows that the model is able to adequately describe
the trend of the data and is able to capture the existing variability in
the GH stimulation test. The GOF figures are shown in Figure S2.
Population model predictions and observations show a high level of
variability, indicative of the variability in GH secretion (Figure S2A). A
small bias can be observed in the CWRESI over time, indicating that
there is an underprediction of the GH concentrations around 2 hours
after dosing (Figure S2C). This bias may originate from endogenous
GH secretion or from a delay in the peak GH concentrations, which
could not be estimated in the current model. A single outlier was iden-
tified (CWRESI = 7.5) which was due to the release of endogenous
GH. The majority of the data (>95%) remains within the acceptance
criteria of [−2,2]. The model was estimated using FOCE+I, ADVAN13,
TOL = 7, NSIG = 3 and SIGL = 6.
3.1.4 | Local sensitivity analysis of system
parameters
Using the estimated model parameters, a 2- and 10-fold change in
the half-life of GHRH, the kact, the pituitary volume or the distribu-
tion volume of GHRH changed the AUC of the GH stimulation by
GHRH (Figure S3A/C). No impact in the median eminence volume
or the ophthalmic artery flow on the AUC were observed. When
the kinact and the GHRH-stimulated secretion were re-estimated with
the altered systems parameters, all scenario's showed equal AUC's
compared to the base model with only a minimal deviation when
the half-life of GHRH was changed (Figure S3B/D). These results
indicate that the kinact and the GHRH-stimulated secretion parameters
can account for a bias in the included system parameters in the
model.
4 | DISCUSSION
The model described here was able to characterize the GH kinetics
and the response to the administration of rhGH and the stimulation
of GH by GHRH in normal weight and obese women. It allowed for
quantification of the level of variability on the CLGH, which was
partly explained by differences in bodyweight, on the VSAC-Slow, and
on the GHRH-stimulated secretion. The study design affected
different parts of the same biological system in the same subjects in
TABLE 3 Parameter estimates of the growth hormone stimulation part of the model
Parameter Estimate [RSE%] (CV%) Shrinkage (%) Bootstrap mean [95%-CI]
kact (/nmol*h) 100
a - -
kinact (/h) 1.46 [4.43] - 1.46 [1.32–1.57]
GHRH-stimulated secretion (mg/h) 99.8 [14.9] - 101.1 [71.0–137.3]
ω2 GHRH-stimulated secretion 0.59 (89.7) < 0.01 0.58 [0.32–0.87]
σ2 proportional error 0.225 3 0.224 [0.178–0.280]
RSE, relative standard error; CV%, coefficient of variation; CI, confidence interval; GHRH, growth hormone-releasing hormone.
aIndicates fixed parameter.
F IGURE 4 Visual predictive check of plasma
growth hormone (GH) concentrations relative to
the time of GH-releasing hormone administration
(vertical dashed line). The black dots represent
the observations, with their 10–50–90%
distribution (black dashed lines). The shaded areas
represent the 95% confidence intervals of the
median prediction (red) and the 10th- and the 90th
prediction interval (blue)
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2 experiments, which allowed for a data-driven approach for the
estimation of the parameters in the model with high parameter
accuracy (RSE < 30%).
Previous research indicated that the volume of distribution of
GH was around 43.8 mL/kg (range 35.4–57.4 mL/kg) in healthy sub-
jects and 54.9 mL/kg (39.9–84.4 mL/kg) in acromegaly patients.39
This would result in a volume of distribution of 3.1 and 3.8 L,
respectively, for a 70-kg person. For a typical subject in our study
(70 kg, 1.7 m) the distribution volume was higher but in the same
order of magnitude (6.1 L), which may be due to the different study
population in our study or differences in statistical methods used in
the calculation of the distribution volume. In our population, no
significant differences between the groups (normal weight, upper
body obese, lower body obese) in the volume of distribution was
identified, indicating that increased weight was of little influence on
the volume of distribution in this population or that the weight and
height dependent system parameters already fully accounted for this
variability. The effect of bodyweight/obesity on GH clearance was
not significant after a noncompartmental analysis previously reported
on the same data.22 The use of a more advanced population NLME
analysis in this study was able to better characterize this significant
linear covariate relationship, in which GH clearance would increase
linearly from 24.7 L/h for a 60-kg subject to 32.1 L/h for a 100-kg
subject.
In the model described here, GH is stimulated by GHRH in an
attempt to quantify the feed-forward mechanism present in GH
control. However, existing biological knowledge reports on several
feedback mechanisms that also control GH secretion (e.g. GH,
somatostatin and IGF-1),40 which cannot be identified using the cur-
rently available data. To quantitate the negative feedback, a different
study design would be required that uses repetitive stimulation
(e.g. multiple doses of GHRH). An alternative approach to estimate
the impact of this feedback component could be the estimation of
pulsatile secretion of GHRH underlying an endogenous GH profile, as
a new component to this model, thus mimicking the hypothalamic
function. Secondly, GH release will increase endogenous somatostatin
concentrations that in turn block the release of GH. As such, a high
burst of GH prior to the start of the experiments will have increased
the endogenous somatostatin concentration, and thereby block part
of the stimulatory exogenous GHRH effects during the experiment.
To identify such feedback mechanisms, measures of target site
concentrations of somatostatin in the anterior pituitary would be
required, which is currently not feasible. In the current model results,
this mechanism may cause the true variability of the GHRH-stimulated
secretion parameter to be overestimated. Additionally, the impact of
the feedback from IGF-1 was assumed to be limited due to the slow
change in response of IGF-1 to increases in GH concentrations.
Despite the omission of several known feedback mechanisms, this
model forms the basis for quantifying the feed-forward relationship
between GHRH and GH and understanding where variability in the
somatotropic axis resides.
The local sensitivity analysis of the system parameters showed
that the re-estimation of the kinact and the GHRH-stimulated secretion
resulted in similar GH AUCs. This indicates that these parameters
remain empirical in nature, since they are able to correct for a possible
bias from system parameters, and therefore cannot be compared
directly with experimental data. Furthermore, the system parameters
were included as point estimates in the model, without any variability
between individuals. Interindividual variability in these values can
account for part of the identified variability in the model in which, for
example, small changes in the half-life of GHRH can impact the
release of GH (Supporting Information Figure S3). Additionally, the
estimated GHRH-stimulated secretion parameter was estimated as a
linear relationship based on a single GHRH dose, the addition of multi-
ple GHRH dosing levels can inform on the shape of this relationship in
future research. This model is therefore an approximation of the bio-
logical system, which, when available, can be updated with additional
information to explain the kact and kinact, or the GHRH receptor
density in the human pituitary.
The data for this analysis were obtained from a heterogeneous
healthy normal weight and obese female population. The structural
model can be used for other populations when taking into account
the general challenges in GH research. Many different reference
standards, sampling methods and GH assays are used, which limits the
comparability between studies.10,41 For example, to account for a dis-
crepancy between different GH assays, the GHRH-stimulated secretion
parameter can be re-estimated, but the other parameters should
remain in the same order of magnitude. Similarly, the use of a
different GHRH analogue, with a different half-life, may increase the
duration of GH stimulation, which can be incorporated in the kel-GHRH
parameter.
In conclusion, the presented model was able to capture the
interaction between GHRH and GH, and quantify the interindividual
variability in GH kinetics and the GH stimulation by GHRH in
healthy and obese women. To improve the robustness of the
model, more data from a larger population with wider distributions
in age and bodyweight in men and women are needed to identify
additional covariates that may explain the currently observed
variability. A future step would be the expansion of this model by
the addition of the hypothalamic control of GHRH to study endog-
enous pulsatile GH secretion in humans and the interaction with
IGF-1.
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